188 related articles for article (PubMed ID: 17981789)
1. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.
Salvatore G; Nappi TC; Salerno P; Jiang Y; Garbi C; Ugolini C; Miccoli P; Basolo F; Castellone MD; Cirafici AM; Melillo RM; Fusco A; Bittner ML; Santoro M
Cancer Res; 2007 Nov; 67(21):10148-58. PubMed ID: 17981789
[TBL] [Abstract][Full Text] [Related]
2. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
4. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
Fischer M; Quaas M; Nickel A; Engeland K
Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
[TBL] [Abstract][Full Text] [Related]
5. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
6. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
[TBL] [Abstract][Full Text] [Related]
7. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.
Ismail IA; Kang KS; Lee HA; Kim JW; Sohn YK
Eur J Pharmacol; 2007 Dec; 575(1-3):12-20. PubMed ID: 17706963
[TBL] [Abstract][Full Text] [Related]
8. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
Jang YJ; Kim YS; Kim WH
Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
[TBL] [Abstract][Full Text] [Related]
10. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6.
Incassati A; Patel D; McCance DJ
Oncogene; 2006 Apr; 25(17):2444-51. PubMed ID: 16369493
[TBL] [Abstract][Full Text] [Related]
11. Plk1 regulates liver tumor cell death by phosphorylation of TAp63.
Komatsu S; Takenobu H; Ozaki T; Ando K; Koida N; Suenaga Y; Ichikawa T; Hishiki T; Chiba T; Iwama A; Yoshida H; Ohnuma N; Nakagawara A; Kamijo T
Oncogene; 2009 Oct; 28(41):3631-41. PubMed ID: 19668228
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.
Nucera C; Eeckhoute J; Finn S; Carroll JS; Ligon AH; Priolo C; Fadda G; Toner M; Sheils O; Attard M; Pontecorvi A; Nose V; Loda M; Brown M
Clin Cancer Res; 2009 Jun; 15(11):3680-9. PubMed ID: 19470727
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide down-regulates polo-like kinase 1 through a proximal promoter cell cycle gene homology region.
Zhang J; Wang S; Kern S; Cui X; Danner RL
J Biol Chem; 2007 Jan; 282(2):1003-9. PubMed ID: 17121839
[TBL] [Abstract][Full Text] [Related]
14. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.
Lei M; Erikson RL
Oncogene; 2008 Jun; 27(28):3935-43. PubMed ID: 18297112
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of human polo-like kinases and early mitotic inhibitor.
Tategu M; Nakagawa H; Sasaki K; Yamauchi R; Sekimachi S; Suita Y; Watanabe N; Yoshid K
J Genet Genomics; 2008 Apr; 35(4):215-24. PubMed ID: 18439978
[TBL] [Abstract][Full Text] [Related]
17. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
18. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
20. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549].
Zhou Q; Bai M; Su Y
Ai Zheng; 2005 Feb; 24(2):149-54. PubMed ID: 15694023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
